DRUG

acriflavine

7 hypotheses across 5 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

acriflavine appears in hypotheses across 5 disease domains: Epilepsy, Glioblastoma, Inflammatory bowel disease, Pancreatic cancer, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: HIF-1α, HIF-1.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for acriflavine

Epilepsy 2

Mediator Outcome Score Tier Lit. status Trial
HIF-1α epilepsy 0.208 Mid novel signal none
HIF-1α hippocampal neuron damage 0.208 Mid novel signal none

Glioblastoma 1

Mediator Outcome Score Tier Lit. status Trial
HIF-1 glioblastoma progression 0.208 Mid novel signal none

Inflammatory bowel disease 1

Mediator Outcome Score Tier Lit. status Trial
HIF-1α ulcerative colitis 0.269 Mid novel signal none

Pancreatic cancer 2

Mediator Outcome Score Tier Lit. status Trial
HIF-1α radiation 0.208 Mid reproduces known none
HIF-1 poor prognosis 0.208 Mid novel signal none

Rheumatoid arthritis 1

Mediator Outcome Score Tier Lit. status Trial
HIF-1α rheumatoid arthritis 0.208 Mid novel signal none

Clinical trials

1 registered trial for acriflavine

Source: ClinicalTrials.gov

← All drugs